Monotherapy using prasugrel failed to show noninferiority compared with potent antiplatelet therapy plus aspirin at the time of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.

Edoxaban did not reduce stroke or systemic embolism but increased major bleeding in high-risk patients with atrial fibrillation who had had an intracranial hemorrhage, according to results presented in a Hot Line session today at ESC Congress 2026.